Media Contact:
Stephen Majors
Vice President, Global Communications
smajors@alliancerm.org
Carlsbad, CA
The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization championing the benefits of engineered cell therapies and genetic medicines, today announced the election of its 2024 Board of Directors.
Washington, DC
The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization representing the engineered cell therapy and genetic medicines sector, announced the promotion of Michael Lehmicke to Senior Vice President, Science & Industry Affairs, effective immediately.
BRUSSELS
Without changes recognizing the unique characteristics of ATMPs, the EU’s new Joint Clinical Assessment will fail to deliver the next generation of transformative therapies to rare disease patients, according to the Alliance for Regenerative Medicine, EveryLife Foundation for Rare Diseases, and Rare Diseases International.
Brussels, BE
The legislative revision is an opportunity for EU policymakers to help address the EU’s stagnation in ATMP clinical trials, company formation, and investment in comparison to the US and China. While the 26 April Commission proposal in some ways improves upon an earlier version, it still falls significantly short of building a sustainable future for the ATMP sector and providing access for EU patients.
